Decoy Therapeutics director granted 2,000 shares

A Decoy Therapeutics director received 2,000 restricted shares that fully vest in August 2027 as part of equity compensation.

Rhea-AI Filing Summary

Decoy Therapeutics Inc. (symbol: DCOY) is the issuer of record for a Form 4 filing submitted to the SEC. Gauthier Patricia G. reported acquisition or exercise transactions in this Form 4 filing.

Decoy Therapeutics Inc. (DCOY) reported that director Patricia G. Gauthier received a grant of 2,000 shares of Common Stock on August 31, 2026. The award was granted at $0.00 per share as restricted stock under the Decoy Therapeutics Inc. 2026 Equity Incentive Plan and 100 percent will vest on August 30, 2027. Following this grant, she directly holds 2,000 shares.

Insider Trade Summary

Grant/Award: 2,000 shares

Grant/Award 1 txn

Insider Gauthier Patricia G.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F1	2,000	$0.00	$0.00

Holdings After Transaction: Common Stock — 2,000 shares (Direct)

Footnotes (1)

1. F1. Restricted stock granted under the Decoy Therapeutics Inc. 2026 Equity Incentive Plan, 100 percent will vest on August 30, 2027.

Key Figures

Restricted stock granted: 2,000 shares Grant price: $0.00 per share Shares held after transaction: 2,000 shares +1 more

4 metrics

Restricted stock granted 2,000 shares Grant to director Patricia G. Gauthier on August 31, 2026

Grant price $0.00 per share Equity grant under 2026 Equity Incentive Plan

Shares held after transaction 2,000 shares Director’s direct holdings following the August 31, 2026 grant

Vesting date August 30, 2027 100 percent of restricted stock vests on this date

Key Terms

Restricted stock, Equity Incentive Plan, vesting

3 terms

Restricted stock financial

"Restricted stock granted under the Decoy Therapeutics Inc. 2026 Equity Incentive Plan"

Shares granted to an individual that carry limits on transfer or sale until certain conditions are met, such as staying with the company for a set time or hitting performance targets. Think of them as a locked gift that gradually opens; for investors they matter because they affect how many shares may enter the market later, signal management incentives and potential dilution, and reveal confidence in future company performance.

Equity Incentive Plan financial

"granted under the Decoy Therapeutics Inc. 2026 Equity Incentive Plan"

An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.

vesting financial

"100 percent will vest on August 30, 2027"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Decoy Therapeutics (DCOY) report for Patricia G. Gauthier?

Decoy Therapeutics reported that director Patricia G. Gauthier received a grant of 2,000 shares of Common Stock as restricted stock on August 31, 2026 under the company’s 2026 Equity Incentive Plan.

At what price were the 2,000 Decoy Therapeutics (DCOY) shares granted?

The 2,000 shares of Decoy Therapeutics Common Stock granted to Patricia G. Gauthier were awarded at a price of $0.00 per share, reflecting an equity compensation grant rather than a market purchase.

When do the restricted shares granted to the Decoy Therapeutics (DCOY) director vest?

The restricted stock granted to Patricia G. Gauthier under the Decoy Therapeutics Inc. 2026 Equity Incentive Plan will 100 percent vest on August 30, 2027, according to the filing footnote.

How many Decoy Therapeutics (DCOY) shares does Patricia G. Gauthier hold after this grant?

Following the reported grant, Patricia G. Gauthier directly holds 2,000 shares of Decoy Therapeutics Common Stock, all attributable to this restricted stock award.

Was the Decoy Therapeutics (DCOY) Form 4 transaction made under a Rule 10b5-1 trading plan?

No. The Form 4 indicates no Rule 10b5-1 trading plan for this transaction, and the document-level checkbox affirming a 10b5-1 plan is not marked as true.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/02/2026 - 05:40 PM EDT Accepted by SEC EDGAR 09/02/2026 - 05:39 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gauthier Patricia G.

(Last) (First) (Middle)

2450 HOLCOMBE BLVD., SUITE X

(Street)

HOUSTON TEXAS 77021

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Decoy Therapeutics Inc. [ DCOY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/31/2026		A(1)		2,000	A	$0	2,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Restricted stock granted under the Decoy Therapeutics Inc. 2026 Equity Incentive Plan, 100 percent will vest on August 30, 2027.

	/s/Mark Rosenblum, as Attorney -in-Fact	09/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)